Obserwuj
James Larkin
James Larkin
Royal Marsden Hospital / Institute of Cancer Research, London, UK
Zweryfikowany adres z rmh.nhs.uk - Strona główna
Tytuł
Cytowane przez
Cytowane przez
Rok
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
91262011
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
M Gerlinger, AJ Rowan, S Horswell, J Larkin, D Endesfelder, E Gronroos, ...
New England journal of medicine 366 (10), 883-892, 2012
85782012
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
79882015
Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
60252015
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
58882015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
36612017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
31052019
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
29812015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
25972012
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ...
New England Journal of Medicine 371 (20), 1867-1876, 2014
23892014
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
22562019
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of oncology 28, iv119-iv142, 2017
22402017
Renal cell carcinoma
JJ Hsieh, MP Purdue, S Signoretti, C Swanton, L Albiges, M Schmidinger, ...
Nature reviews Disease primers 3 (1), 1-19, 2017
22292017
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
22262017
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
20002014
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
17832018
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
15512015
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ...
New England Journal of Medicine 377 (19), 1813-1823, 2017
15152017
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ...
The Lancet Oncology 19 (11), 1480-1492, 2018
13722018
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ...
Nature genetics 46 (3), 225-233, 2014
13692014
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20